PF-04634817

CAT: 0804-HY-117621Size: 1 EachDry Ice: NoHazardous: No
CAT#:0804-HY-117621Size:1 Each
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
PF-0463481 is a potent and orally active dual CCR2/CCR5 antagonist with comparable human and rodent CCR2 potency (rat IC50=20.8 nM), and displays 10-20 fold less rodent CCR5 potency (rat IC50=470 nM) . PF-0463481 is safe and well-tolerated and has the potential for the study of diabetic nephropathy[3].
CAS Number
[1228111-63-4]
UNSPSC
12352005
Target
CCR
Type
Reference compound
Related Pathways
GPCR/G Protein; Immunology/Inflammation
Applications
Neuroscience-Neuromodulation
Field of Research
Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/pf-04634817.html
Purity
98.87
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
O=C(N1[C@@]2([H])C[C@@]([H])(C1)N(C3=NC=NC(C(F)(F)F)=C3)C2)[C@@]4(C[C@@H](CC4)N[C@@H]5[C@@H](COCC5)OC)C(C)C
Molecular Formula
C25H36F3N5O3
Molecular Weight
511.58
References & Citations
[1]Gale JD, et al. A CCR2/5 Inhibitor, PF-04634817, Is Inferior to Monthly Ranibizumab in the Treatment of Diabetic Macular Edema. Invest Ophthalmol Vis Sci. 2018 May 1;59 (6) :2659-2669.|[2]Gale JD, et al. Effect of PF-04634817, an Oral CCR2/5 Chemokine Receptor Antagonist, on Albuminuria in Adults with Overt Diabetic Nephropathy. Kidney Int Rep. 2018 Aug 3;3 (6) :1316-1327.|[3]Tesch GH, et al. Combined inhibition of CCR2 and ACE provides added protection against progression of diabetic nephropathy in Nos3-deficient mice.Am J Physiol Renal Physiol. 2019 Dec 1;317 (6) :F1439-F1449.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
CCR2; CCR5